You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
ZeClinics said it will use the CRISPR-Cas9 technology to create various zebrafish knockout variants for use as disease models.
The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.
The Financial Times reports gene-edited crops and livestock may soon be allowed in the UK.
Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.
Vivlion, which also holds a license to Goethe University Frankfurt's CRISPR technology, will use the license to offer R&D reagents and screening services.
Researchers are hoping to make the technology a success for the environment and human health while avoiding the biases that resulted from the debate over GMOs.
Synthego has developed an off switch for CRISPR by engineering a guide RNA that can be controlled through exposure to UV light.
FASMAC provides food analysis and biotech products and services, including DNA/RNA synthesis, DNA sequencing, food testing, and genetic analysis reagents.
Emmanuelle Charpentier and Jennifer Doudna have won this year's Nobel Prize in Chemistry for their work developing the CRISPR gene editing tool, according to Reuters.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.